Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q6UWR7
UPID:
ENPP6_HUMAN
Alternative names:
Choline-specific glycerophosphodiester phosphodiesterase; Ectonucleotide pyrophosphatase/phosphodiesterase family member 6
Alternative UPACC:
Q6UWR7; Q4W5Q1; Q96M57
Background:
Glycerophosphocholine cholinephosphodiesterase ENPP6, also known as Choline-specific glycerophosphodiester phosphodiesterase, plays a crucial role in cellular choline supply by hydrolyzing glycerophosphocholine (GPC) and lysophosphatidylcholine (LPC). It exhibits a preference for LPC with short or polyunsaturated fatty acids, contributing significantly to cellular lipid metabolism and signaling.
Therapeutic significance:
Understanding the role of Glycerophosphocholine cholinephosphodiesterase ENPP6 could open doors to potential therapeutic strategies. Its pivotal function in choline metabolism and lipid signaling pathways suggests its potential as a target for therapeutic intervention in metabolic disorders.